1-8 of 8
Nicola Foot
Close
Sort by
Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Clinical Trials & Observations
Richard Dillon, Robert Hills, Sylvie Freeman, Nicola Potter, Jelena Jovanovic, Adam Ivey, Anju Shankar Kanda, Manohursingh Runglall, Nicola Foot, Mikel Valganon, Asim Khwaja, Jamie Cavenagh, Matthew Smith, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Steven Knapper, Harpreet Kaur, David Taussig, Priyanka Mehta, Kavita Raj, Igor Novitzky-Basso, Emmanouil Nikolousis, Robert Danby, Pramila Krishnamurthy, Kate Hill, Damian Finnegan, Samah Alimam, Erin Hurst, Peter Johnson, Anjum Khan, Rahuman Salim, Charles Craddock, Ruth Spearing, Amanda Gilkes, Rosemary Gale, Alan Burnett, Nigel H. Russell, David Grimwade
Journal: Blood
Blood (2020) 135 (9): 680–688.
https://doi.org/10.1182/blood.2019002959
Published: 2020
Includes: Supplemental data
Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Ing S Tiong, MBChB,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MBBS,PhDFRACP, FRCPA, Catherine Vassili, RN,MN, Vanessa Roma Donati, RN, David Taussig, PhD MRCP, FRCPath, Nicola Potter, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Mikel Valganon, PhD, Nigel H. Russell, MD, Kavita Raj, MD PhD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Andrew Grigg, Steven Knapper, DM, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2648.
https://doi.org/10.1182/blood-2019-123899
Published: 2019
Journal Articles

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Richard Dillon, MA, PhD MRCP, FRCPath, Jelena Jovanovic, PhD, Nicola Potter, PhD, Nicola Foot, MSc, Matthew J Ahearne, MD MBBS, Sandrine Jayne, PhD, Michael Dennis, MD MRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Martin J.S. Dyer, Paresh Vyas, Lynn Quek, FRCPath, DPhil, MBBS, Nigel H. Russell, Robert K. Hills, MA, DPhil, MSc, Ellen Solomon, PhD, David Grimwade, PhD MRCP, MRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 2570.
https://doi.org/10.1182/blood-2018-99-114233
Published: 2018
Journal Articles

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Richard Dillon, MA, PhD MRCP, FRCPath, Robert K. Hills, MA, DPhil, MSc, Sylvie D Freeman, MBChB, DPhil, Nicola Potter, PhD, Adam Ivey, BSc, MSc, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Laura Upton, Asim Khwaja, MD PhD, Jamie Cavenagh, MD PhD, Ruth Spearing, MD, Alan K. Burnett, MD, Nigel H. Russell, David Grimwade, PhD MRCP, MRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 2739.
https://doi.org/10.1182/blood-2018-99-113662
Published: 2018
Journal Articles

Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, DipRCPath, Simon Hallam, MRCP, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath
Journal: Blood
Blood (2007) 110 (11): 2713.
https://doi.org/10.1182/blood.V110.11.2713.2713
Published: 2007
Journal Articles

A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, BSc, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath
Journal: Blood
Blood (2006) 108 (11): 3542.
https://doi.org/10.1182/blood.V108.11.3542.3542
Published: 2006
Journal Articles

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Rakesh Popat, MBBS, Heather E. Oakervee, MRCPath, Nicola Curry, MBBS, Nicola Foot, BSc, Curly Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David Schenkein, MD, Dixie-Lee Esseltine, MD, Jamie D. Cavenagh, MD
Journal: Blood
Blood (2005) 106 (11): 2554.
https://doi.org/10.1182/blood.V106.11.2554.2554
Published: 2005
Journal Articles

A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Heather E. Oakervee, MRCPath, Nicola Foot, BSc, Samir Agrawal, PhD, Patricia Smith, RGN, Charles Craddock, FRCPath, Catherine Williams, FRCPath, Supratik Basu, FRCPath, Jamie D. Cavenagh, MD
Journal: Blood
Blood (2005) 106 (11): 2555.
https://doi.org/10.1182/blood.V106.11.2555.2555
Published: 2005